WO2004050121A1 - Pharmaceutical compositions of cell lysate and processes for the production and use thereof - Google Patents
Pharmaceutical compositions of cell lysate and processes for the production and use thereof Download PDFInfo
- Publication number
- WO2004050121A1 WO2004050121A1 PCT/EP2003/050891 EP0350891W WO2004050121A1 WO 2004050121 A1 WO2004050121 A1 WO 2004050121A1 EP 0350891 W EP0350891 W EP 0350891W WO 2004050121 A1 WO2004050121 A1 WO 2004050121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell lysate
- pharmaceutical composition
- xanthan gum
- solution
- composition
- Prior art date
Links
- 239000013592 cell lysate Substances 0.000 title claims abstract description 119
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 61
- 230000008569 process Effects 0.000 title claims abstract description 52
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 130
- 239000000725 suspension Substances 0.000 claims abstract description 87
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 38
- 229920001285 xanthan gum Polymers 0.000 claims description 91
- 239000000230 xanthan gum Substances 0.000 claims description 87
- 235000010493 xanthan gum Nutrition 0.000 claims description 87
- 229940082509 xanthan gum Drugs 0.000 claims description 87
- 229920002774 Maltodextrin Polymers 0.000 claims description 63
- 239000005913 Maltodextrin Substances 0.000 claims description 63
- 229940035034 maltodextrin Drugs 0.000 claims description 63
- 210000002510 keratinocyte Anatomy 0.000 claims description 34
- 239000006166 lysate Substances 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 32
- 230000002934 lysing effect Effects 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 9
- 206010052428 Wound Diseases 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 239000003981 vehicle Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 206010040943 Skin Ulcer Diseases 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 231100000019 skin ulcer Toxicity 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 107
- 238000004062 sedimentation Methods 0.000 description 43
- 238000005189 flocculation Methods 0.000 description 38
- 238000009472 formulation Methods 0.000 description 38
- 230000016615 flocculation Effects 0.000 description 37
- 238000000265 homogenisation Methods 0.000 description 37
- 229930006000 Sucrose Natural products 0.000 description 33
- 239000005720 sucrose Substances 0.000 description 33
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 26
- 239000007979 citrate buffer Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000872 buffer Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 238000012545 processing Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229920001983 poloxamer Polymers 0.000 description 7
- 239000013049 sediment Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010894 electron beam technology Methods 0.000 description 5
- 239000008394 flocculating agent Substances 0.000 description 5
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013376 serial cultivation Methods 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s).
- the pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates.
- the present invention fiirther discloses processes for the production and the use of the pharmaceutical composition.
- a wound healing composition such as a keratinocyte cell lysate, and in particular cultured human keratinocyte cell lysates
- rapid aggregation, flocculation and partial sedimentation of the cell lysate contained in these solutions or suspensions is observed after the homogenization (lysis) steps in the production process.
- Such aggregation, flocculation and/or sedimentation results in lack of homogeneity in the solution or suspension of the cell lysate and further complicates its processing, in some cases, this can even render the composition unusable for its intended purpose.
- modifications that can aid the processing step before or after homogenization by preventing flocculation or sedimentation.
- xanthan gum as a thickening agent, which increases viscosity of the suspension and is suitable for preventing sedimentation of the solid drug particles.
- xanthan gum has also been used to suspend large biological particles for the purpose of stabilizing cell suspensions during flow cytometry, thereby preventing sedimentation (Cytometry 10: 803-806 (1989)).
- Another example shows that the presence of xanthan inhibited the aggregation and demixing of whey protein isolates and resulted in a homogenous mixture (Food Hydrocolloids 12: 469-479 (1998)).
- Cell lysates result from the lysis of cells, which releases many components in various forms, forming an extremely complex mixture of constituents such as proteins, glycoproteins, polysaccharides, lipids, nucleic acids etc. All these components may interact with each other, significantly increasing the possibility for complex formation and flocculation, ultimately resulting in a non-stable solution or suspension and sedimentation of part of these components. Accordingly, it can be seen that there remains a need to provide a homogenous stable pharmaceutical composition comprising cell lysates.
- One example of such a composition contains a keratinocyte cell lysate, which is suitable for wound healing purposes.
- Such pharmaceutical composition of cell lysates in the form of a solution or a suspension, which are homogenized and if required further processed by drying or freeze-drying.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a cell lysate and at least one antiflocculant and/or antisedimentation agent(s).
- the present invention further provides a homogeneous pharmaceutical composition in a dried or freeze-dried form.
- the present invention provides a pharmaceutical composition comprising a cell lysate and at least one antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant/antisedimentation agent is xanthan gum.
- the present invention further provides a pharmaceutical composition, in which the antiflocculant and/or antisedimentation agent is a combination of xanthan gum and maltodextrin.
- the pharmaceutical composition may comprise a buffering agent.
- buffers which are useful in this regard, include citrate buffers, phosphate buffers, or any other suitable buffer known in the art, preferably clinically acceptable buffering agents.
- the present invention further provides a process for the production of a pharmaceutical composition of cell lysate in the form of a solution or a suspension that is substantially free of inconsistencies.
- An example of such a pharmaceutical composition is a homogeneous freeze-dried pharmaceutical composition of a keratinocyte cell lysate.
- the present invention also provides processes for the production of a homogenized, sterilized composition of a keratinocyte cell lysate in the form of a solution or a suspension.
- the pharmaceutical composition of the present invention may be useful for various therapeutic applications and may further comprise a pharmaceutically acceptable carrier or vehicle or recipient.
- a pharmaceutically acceptable carrier or vehicle or recipient is a composition of keratinocyte cell lysate useful in the treatment of wounds such as burn wounds or skin ulcers.
- the present invention provides a pharmaceutical composition for promoting the healing of a wound; wherein said composition comprises a non-viable keratinocyte lysates and a pharmaceutically acceptable vehicle.
- the said pharmaceutically acceptable vehicle is a dry powder, suspension or solution. Further in this regard, the said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix other than a gel.
- the present invention also provides a process for treating a surface wound to promote healing in a mammal comprising the step of:
- the present invention disclosed herein is a pharmaceutical composition of cell lysate in the form of a solution or a suspension, or a freeze-dried form thereof, further characterized in that it is substantially free of inconsistencies.
- This solution or suspension of the cell lysate or the freeze-dried form thereof comprises xanthan gum and or maltodextrin that acts as an anti-flocculant agent(s) for preventing the formation of flocculants in the solution or suspension that may sediment.
- the present invention discloses a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture.
- the said agent is xanthan gum or combination of xanthan gum and maltodextrin which prevents the formation of flocculants at may sediment in the solution or suspension.
- this process may optionally include the freeze-drying or otherwise drying of the solution or suspension to obtain a water- free product.
- a pharmaceutical composition of the present invention is a composition of cell lysate in the form of a solution or a suspension.
- These pharmaceutical compositions containing a cell lysate further comprise a buffer component and at least one anti-flocculant and/or anti-sedimentation agent.
- These compositions may be further processed by freeze-drying or otherwise drying, resulting in a substantially water-free product with even better long- term stability.
- the term "inconsistencies" refers to the situation where the composition of the cell lysate is not homogeneous, in such a way that the composition of one part of the lysate may differ from the composition of another part of the lysate.
- cell lysate refers to non-viable cell suspensions or fractions thereof, obtained by lysing the cells.
- the cell lysate in the solution or suspension of the present invention may be whole cells, parts of cells or any fractions or mixtures thereof obtained after a lysis step.
- the cell lysate may be obtained by any of the various processes which are well-known to those skilled in the art. For example, whole cells may be obtained as described in US 6,126,935.
- Parts of cells may be obtained by lysing whole cells, subjecting the resulting lysate to centrifugation wherein certain parts of the resulting cell lysate are in the pellet fraction and certain other parts of the resulting cell lysate are in the supernatant and only one of the two parts are used.
- An example of such a process is disclosed in US 6,126,935.
- cell lysis refers to any type of cell (i.e. prokaryotic or eukaryotic) and involves the action of rapturing the cell wall and/or the cell membrane of cells (present in the form of solution or suspension) subjected to a treatment which may include chemical, biological, mechanical or thermal treatment, possibly resulting in the release of its biological constituents.
- Cell lysates may be obtained by mechanically homogenizing the cells.
- the Keratinocyte cell lysates of the present invention may preferably be obtained by a process as described in US 6,126,935.
- homogenization or homogenizing used in the present context denotes the processing of the cell lysate mixture by making the said mixture homogeneous in such a way as to ensure that any given part of the above mentioned mixture has the same composition and physico-chemical properties as any other part of that same mixture.
- homogenization or homogenizing may also refer to lysis in the sense that certain homogenization procedures also lead to cell lysis.
- concentration of cell lysate in a composition of the present invention varies according to the type of cell lysate in the composition, as well as according to its intended use.
- the concentration of cell lysate ranges from 0.02 to 5 % w/v (percentage refers to weight percentage of total protein in the cell lysate, as dete ⁇ nined by a suitable protein quantification assay).
- concentration of the cell lysate ranges from 0.05 to 2 % w/v. More preferably, the concentration of the cell lysate ranges from 0.1 to 1 % w/v.
- the liquid component of the solutions/suspensions of the present invention may be any liquid suitable for supporting the cell lysate in the solution or suspension.
- liquid components examples include water, oil, or emulsions (such as water-in-oil or oil-in-water emulsions) and other similar liquids.
- emulsions such as water-in-oil or oil-in-water emulsions
- isotonic solution of sodium chloride for osmotic adjustment
- phosphate buffer and lysed cells is contemplated.
- this is supplemented with a solution of a lyoprotectant (such as sucrose, maltodextrin, glycine, sorbitol, trehalose, polyvinylpyrrolidone, polyethylene glycol or any other suitable lyoprotectant or combination thereof) and a citrate buffer (such as sodium citrate) for aiding the subsequent freeze-drying of the composition.
- a lyoprotectant such as sucrose, maltodextrin, glycine, sorbitol, trehalose, polyvinylpyrrolidone, polyethylene glycol or any other suitable lyoprotectant or combination thereof
- a citrate buffer such as sodium citrate
- a pharmaceutical composition of the present invention in addition may contain other buffers or buffer systems.
- buffers may include phosphate, citrate or any other compositions, which can act as a pH-buffer.
- the present invention involves a pharmaceutical composition obtained by a process comprising the step of lysing the cells prior to adding at least one anti-flocculant and/or anti-sedimentation agent to the composition of a non-viable cell lysate solution or suspension.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a cell lysate and antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant/antisedimentation agent is xanthan gum
- Xanthan gum may be obtained commercially or by fermentation.
- concentration of xanthan gum in the pharmaceutical composition of cell lysate of the present invention will range from 0.001 to 5 % w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5 % w/v.
- the present invention involves a pharmaceutical composition of keratinocyte cell lysate
- the use of xanthan gum aids in preventing flocculation and sedimentation in the keratinocyte cell lysate solution or suspension prior to or during use or further processing. Accordingly, the formation of inconsistencies in the solution or suspension is avoided. This facilitates further processing and use of the keratinocyte cell lysate solution or suspension for the formation of a composition useful in wound healing, for example, for the treatment of skin ulcers or burns.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a cell lysate and antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant/antisedimentation agent is maltodextrin.
- concentration of maltodextrin in the solutions/suspensions of the present invention may range from 0.01 to 10 % w/v. Alternatively; a concentration of maltodextrin ranging from 0.5 to 2 % w/v may be used.
- the composition of the present invention it is noted that in certain circumstances, it is desirable for the composition of the present invention to have a particular pH and/or be maintained within a specific pH range.
- a buffer is employed for this purpose.
- buffers which are useful in this regard, include citrate buffers, phosphate buffers, or any other suitable buffer known in the art, preferably also clinically acceptable.
- concentration of buffer to include in the final solution or suspension will vary according to various factors including the strength of the buffer and the pH, which is required for the composition.
- the final concentration of buffer in the composition of the invention will range from 5 to 200 mM, preferably from 10 to 100 mM, more preferably from 20 to 50 mM. This can be achieved by adding a concentrated buffer stock solution, for instance with a concentration of approximately 1500 mM, to the composition.
- a concentrated buffer stock solution for instance with a concentration of approximately 1500 mM.
- the pharmaceutical compositions and particularly if the solutions/suspensions of the present invention are to be dried or freeze-dried, they may further include sucrose.
- the concentration of sucrose in the composition of the present invention will vary according to the type of composition, as well as according to the use to which the composition will be placed.
- the concentration of sucrose ranges from 1 to 30 % w/w, preferably from 2 to 20 % w/w, more preferably from 5 to 10 % w/w. This can be achieved by adding sucrose powder or a concentrated sucrose stock solution, for instance with a concentration of approximately 50 %, to the composition. It will be clear that instead of sucrose, a suitable concentration of another lyoprotectant may also be used, such as glycine, trehalose, sorbitol, polyvinyl pyrrolidone, polyethylene glycol or any other suitable lyoprotectant or combination thereof known in the art.
- sucrose a suitable concentration of another lyoprotectant may also be used, such as glycine, trehalose, sorbitol, polyvinyl pyrrolidone, polyethylene glycol or any other suitable lyoprotectant or combination thereof known in the art.
- the pharmaceutical composition of the present invention may further include such other and different ingredients as may be desirable for the particular cell lysate implicated and/or use for which the composition is intended. It is possible that the solutions/suspensions of the present invention may further include additional components, some of which being a consequence of obtaining the biological (cellular) material. Examples of such ingredients include proteins, culture media, washing media and other organic and/or inorganic material that has a tendency to flocculate and/or sediment or provoke the flocculation and/or sedimentation of the other constituents.
- the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture.
- the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, xanthan gum is added as a antiflocculant and/or antisedimentation agent to stabilize the cell lysate mixture.
- the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, a mixture of xanthan gum and maltodextrin is added as antiflocculant and/or antisedimentation agents to stabilize the cell lysate mixture.
- the present invention involves a process for the production of various pharmaceutical compositions of biological materials in the form of a solution or a suspension or freeze-dried solution or suspension, including compositions used to produce a composition of cell lysate in the form of a solution or a suspension or freeze- dried solution or suspension.
- a process for the present invention to produce a composition of keratinocyte cell lysate in the form of a solution or a suspension or freeze-dried solution or suspension.
- the solution or suspension is formed by combining (such as, for example, by mixing) the cell lysate, obtainable by any process known to those skilled in the art, with one or more suitable excipients, possibly in a liquid form. This may be achieved by any process well known to those skilled in the art, which is suitable for use with the particular biological material andor liquid component involved.
- the solution or suspension of cell lysate will be formed by obtaining the cell lysate and the excipients (possibly in liquid form), either individually or at the same time, and mixing the cellular matter with the excipients in such a manner that a solution or a suspension of the cell lysate is formed.
- the keratinocyte cell lysate may be prepared in the form of an isotonic solution of sodium chloride 0.9 % (w/w), phosphate-buffered saline or any other suitable medium.
- the cell lysate is then homogenized mechanically and may be stored if required at -70°C.
- the frozen homogenate is then thawed and supplemented with the addition thereto of the excipients comprised of sucrose to a final concentration of 6.5 % (as a lyoprotectant) and citrate buffer to a final concentration of 30 mM
- concentration of cell lysate and the liquid component to be added to the composition in the process of the present invention will vary according to the type of cell lysate in the composition, as well as according to its intended use.
- Adding the xanthan gum to the suspension or solution of cell lysate may be performed in any suitable manner well-known to those skilled in the art. For example, this may be done by adding the xanthan gum in its solid state to the solution or suspension under conditions which facilitate its dissolution and homogeneous distribution throughout the solution or suspension or it may be first dissolved in a liquid, such as water, before being added to the suspension/solution of cell lysate. As was noted above, the addition of this xanthan gum, immediately after the homogenization still permits the xanthan gum to exercise its anti-flocculation/anti-sedimentation properties without subjecting the xanthan gum to the homogenization process which negatively impacts its viscosity properties.
- the process for the production of a composition of cell lysate that is in the form of a solution or a suspension of the present invention may further comprise homogenization of the formed composition of cell lysate of the present invention prior to the adding of the xanthan gum thereto.
- Homogenization may be performed by using any known suitable homogenization techniques which is well known to those skilled in the art, including mechanical and chemical processes, and under such process conditions as is needed to lyse the cells as needed.
- keratinocyte lysate solutions/suspensions is homogenizing the solution or suspension by high-pressure homogenization.
- Such homogenization may be conducted using any appropriate apparatus, such as a cell breaker (Constant systems, U.K.).
- homogenization is conducted at a pressure of 2000 bar between 4 and 20°C.
- the result is a cell lysate in the form of a suspension.
- anti-flocculants are added to compositions of cell lysate before homogenization. This is done for ease of processing and to help prevent flocculation during homogenization.
- the process for the production of a composition of cell lysate that is in the form of a solution or a suspension of the present invention may further be comprised of adding a citrate buffer and/or sucrose (both being obtained as described above) to the compositions of cell lysate of the present invention in concentrations, as were also set forth above.
- compositions and the processes of the present invention are of particular application in and of particular interest to the formation of a pharmaceutical composition of keratinocyte cell lysates that are in the form of a solution or a suspension.
- keratinocyte cell lysates may be obtained as described in US 6,126,935.
- solutions/suspensions of cell lysate include xanthan gum that acts as an anti-flocculant agent for preventing the formation of flocculants that may sediment in the solution or suspension.
- the final concentration of xanthan gum in the pharmaceutical composition (in form of solution or suspension) of the cell lysate of the present invention will range from 0.001 to 5 % w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5 % w/v.
- the pharmaceutical composition of cell lysate of the present invention may further include maltodextrin that acts as an anti-flocculant agent for preventing the formation of floccules that may sediment within the solution or suspension.
- the final concentration of maltodextrin in a pharmaceutical composition of cell lysate of the present invention may range from 0.01 to 10 % w/v, more preferably 0.1 to 5 % w/v most preferably 0.5 to 2 % w/v.
- a pharmaceutical composition of cell lysate of the present invention may further include a citrate buffer and/or sucrose.
- a pharmaceutical composition of cell lysate of the present invention may further include an excipient and, in particular, a gel-fo ⁇ ning excipient.
- composition of cell lysate of the present invention is homogenized.
- the homogenized composition is further processed by drying. Drying may be performed in various ways known in the art, such as evaporation, vacuum-drying, spray drying, fluidized bed drying, infrared drying, microwave drying or otherwise removing the water present in the solution or suspension, as long as the drying process does not negatively impact the properties of the final composition.
- Drying may be performed in various ways known in the art, such as evaporation, vacuum-drying, spray drying, fluidized bed drying, infrared drying, microwave drying or otherwise removing the water present in the solution or suspension, as long as the drying process does not negatively impact the properties of the final composition.
- One of the many preferred methods for removing the water is by freeze-drying.
- the process of the present invention is used to produce a composition of cell lysate in the form of a solution or a suspension and, more particularly, a composition of keratinocyte cell lysate in the form of a solution or a suspension, possibly in a dried form.
- the final concentration of xanthan gum added to the pharmaceutical composition of cell lysate of the present invention may range from 0.001 to 5 % w/v. In another embodiment, the concentration of xanthan gum may range from 0.05 to 0.5 % w/v.
- the process for the production of a composition of cell lysate that is in the form of a solution or a suspension of the present invention may further include adding maltodextrin to the composition of cell lysate, whereby the maltodextrin acts as an anti-flocculant agent for preventing the formation of flocculants that may sediment within the solution or suspension.
- the final concentration of maltodextrin added to a pharmaceutical composition of cell lysate of the present invention may range from 0.01 to 10 % w/v.
- a concentration of maltodextrin ranging from 0.5 to 2 % w/v may be adequate.
- the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing by a high-pressure homogenization, a mixture of xanthan gum and/or maltodextrin are added as a antiflocculant and/or antisedimentation agents to stabilize the cell lysate mixture.
- the present invention involves a process for the production of a homogenized pharmaceutical composition
- a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying of keratinocyte cells, which process is characterized in that, immediately after lysing by a high-pressure homogenization, a mixture of xanthan gum and/or maltodextrin is added as a antiflocculant and/or antisedimentation agents to stabilize the keratinocyte cell lysate mixture.
- compositions of cell lysate in the form of a solution or a suspension of the present invention obtainable by a process of the present invention.
- compositions of keratinocyte cell lysate in the form of a solution or suspension obtained by the process of the present invention.
- a pharmaceutical composition comprising a keratinocyte cell lysate is in a freeze-dried or otherwise dried form.
- compositions containing an efficient amount of cell lysate or fractions of cell lysates are administered via different carrier systems and drag dosage forms such as creams, ointments, gels, powders, sprays, solutions, suspensions, emulsions, lyopliilized powders, aerosols.
- composition of a cell lysate in the form of a solution or a suspension obtained by a process including forming a cell lysate in the form of a solution or a suspension, adding at least one anti-flocculant and or at least one anti-sedimentation agent to the composition of a cell lysate in the form of a solution or suspension and stabilizing the composition of a cell lysate solution or suspension to which the at least one anti-flocculant and/or at least one anti-sedimentation agent has been added.
- composition of a cell lysate solution or suspension of the present invention obtainable by a process comprising the step of lysing the cells prior to adding at least one anti-flocculant and/or at least one anti-sedimentation agent to the composition of a non-viable cell lysate solution or suspension.
- One such method of lysing may be by high-pressure homogenization.
- composition of a cell lysate solution or suspension of the present invention obtainable by a process comprising the step of lysing the cells prior to adding xanthan gum at a concentration ranging from 0.001 to 5% w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5% w/v as a anti-flocculant and/or at least one anti-sedimentation agent to the composition of a non-viable cell lysate solution or suspension.
- One such method of lysing may be by high-pressure homogenization.
- composition of a cell lysate solution or suspension of the present invention obtainable by a process comprising the step of lysing the cells prior to adding a combination mixtures thereof of xanthan gum at a concentration ranging from 0.001 to 5% w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5% w/v and maltodextrin at concentration ranging from 0.01 to 10% w/v, more preferably 0.5 to 2% w/v as anti-flocculant and/or at least one antisedimentation agents to the composition of a non-viable cell lysate solution or suspension.
- One such method of lysing may be by high-pressure homogenization.
- the process for the production of a composition of cell lysate that is in the form of a solution or a suspension (possibly in a dried or freeze-dried form) of the present invention may be further comprised of sterilizing the composition of cell lysate following adding the xanthan gum thereto.
- sterilization may be performed chemically, by heat treatment (including the use of microwave energy) or by irradiation, such as UN, gamma or electron beam irradiation.
- the sterilization is performed preferably on the composition after drying (such as freeze-drying or spray drying), in order to minimize possible effects on the biological activity of the composition.
- compositions of cell lysate of the present and the processes for their production are now presented for the purposes of illustration only and are not meant to be, nor should they be, read as being restrictive. Modifications of the compositions, processes, uses and methods disclosed above may be made without departing from the basic spirit of the invention. Accordingly, it will be appreciated by those skilled in the art that within the scope of the appended claims, the invention may be practiced other than has been specifically described herein.
- Example 1 Culturing of human keratinocytes and preparation of a keratinocyte cell lysate Keratinocytes are isolated from neonatal human foreskin.
- a foreskin specimen is incubated overnight at 4°C in a solution containing 25U/mL Dispase in order to obtain separation of epidermis and dermis.
- the epidermal part is collected and further processed by incubation for 30 minutes at 37°C in a solution containing 0.05 % trypsin and 0 .02 % EDTA in order to obtain single keratinocyte cells.
- the trypsin is then neutralized by adding a trypsin inhibitor and the cells are centrifuged, resuspended in a DMSO-containing cryopreservation solution and cryopreserved in liquid nitrogen.
- isolated keratinocytes are cultured using the 3T3 feeder fibroblast technique (Rheinwald J and Green H. Cell (1975) 6: 331-344: Serial cultivation of strains of human epidermal keratinocytes: the formation of keiatinizing colonies from single cells) or in a commercially available low calcium keratinocyte medium. After culturing, the cells are collected mechanically by scraping in an isotonic solution containing sodium chloride and phosphate buffer, homogenized mechanically and frozen at -70°C.
- Example 2 Use of xanthan gum and/or maltodextrin to prevent flocculation and sedimentation
- Unprocessed bulk lysate was prepared as described in example 1.
- Formulated bulk product constituted 200 g of BUP (containing approx. 2 mg/ml of total protein) to which 13g of sucrose powder was added. This material was divided into three aliquots and processed as follows: Aliquot IA was processed through a Constant Systems high-pressure homogenizer at 800 bar (one cycle). After processing, 12.5 ml of the homogenized material was supplemented with either :
- Example 3 Use of xanthan gum/maltodextrin to prevent flocculation and sedimentation of concentrated lysate suspension
- Preparation of unprocessed bulk lysate (BUP) was done as described in example: 1.
- Preparation of formulated bulk product was as follows :
- Formulation A (no antiflocculant): 64 ml of solution 2 was processed through a Constant Systems homogenizer at 800 bar and then supplemented with 52 ml of water
- Formulation B (with antiflocculant): 64 ml of solution 2 was processed through a Constant Systems homogenizer at 800 bar and then supplemented with
- Formulation C (with antiflocculant, no sucrose): 64 ml of solution 1 was processed through a Constant Systems homogenizer at 800 bar and then supplemented with 29 ml of water and 23 ml of a solution containing 5% maltodextrin and 0.5% xanthan gum
- Example 4 Use of xanthan gum or xanthan e im/maltodextrin to prevent flocculation and sedimentation of lysate suspensions containing different protein concentrations - Preparation of unprocessed bulk lysate (BUP) as described in example 1 Preparation of formulated bulk product:
- Formulation 0.3XA and 0.3XB Formulation 0.3XA is prepared by adding the following components to 25g of formulation 1XA :
- Formulation 0.3XB is prepared by adding the following components to 25g of formulation lXB :
- Example 5 Use of xanthan gum or xanthan gum maltodextrin to prevent flocculation and sedimentation of lysate suspensions and effect of timing of adding the antiflocculants - Preparation of unprocessed bulk lysate (BUP) as described in example 1 Preparation of formulated bulk product:
- Homogenized material was divided over 2 aliquots of 80 g each to which either 20 g of a solution containing 5% maltodextrin/0.5% xanthan gum (formulation A) or 20 g of a solution containing 0.5 xanthan gum (formulation B) was added.
- xanthan gum has a similar efficacy for inhibiting flocculation and sedimentation of the lysate suspension as the combination nraltodextrin/xanthan gum. It also confirms the surprising finding that the addition of the antiflocculant needs to occur after the high pressure homogenization step in order to be effective. Addition of the antiflocculant is preferably done as soon as possible after the homogenization in order to minimize subsequent flocculation.
- Example 6 Use of xanthan gum, maltodextrin or xanthan gum ⁇ naltodextrin to prevent flocculation and sedimentation of lysate suspensions and effect of addition before or after homogenization
- Formulation 3 Xanthan gum 0.1%
- M Maltodextrin 1% or 5%
- X xanthan gum 0.1%
- S sucrose: 6.5%
- Example 7 Use of xanthan gum/maltodextrin to prevent flocculation and sedimentation of lysate suspensions of different concentrations in the presence or absence of sucrose
- - Sucrose powder 6.5 g Homogenization through high pressure homogenizer at 800 bar. Homogenized material was divided over 2 aliquots of 25 ml each to which either 25 ml water (formulation A) or 15 ml water and 10 ml of a solution containing 5% maltodextrin/0.5% xanthan gum (formulation B) was added.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising a nonviable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.
Description
Pharmaceutical compositions of Cell lysate and Processes for the Production and
Use Thereof
Field of the invention The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention fiirther discloses processes for the production and the use of the pharmaceutical composition.
Background of the Invention
In the production of a pharmaceutical composition of non-viable cell preparations in the form of a solution or a suspension, such as cell lysates, problems are often encountered with aggregation, flocculation and/or sedimentation. This problem causes inhomogeneity in the product, leading to qualitative or quantitative inconsistencies, particularly in case the product has to be dispensed over multiple containers. In addition, it may cause lack of homogeneity between multiple batches of the product. For example, in the production of a wound healing composition such as a keratinocyte cell lysate, and in particular cultured human keratinocyte cell lysates, rapid aggregation, flocculation and partial sedimentation of the cell lysate contained in these solutions or suspensions is observed after the homogenization (lysis) steps in the production process. Such aggregation, flocculation and/or sedimentation results in lack of homogeneity in the solution or suspension of the cell lysate and further complicates its processing, in some cases, this can even render the composition unusable for its intended purpose. Thus there is a need for modifications that can aid the processing step before or after homogenization by preventing flocculation or sedimentation. It is well known that chemical agents stimulate flocculation or aggregation of proteins leading to precipitation. U.S. Patent No. 4,565,635 describes a water soluble chemical agent "xanthan gum", known to function as a flocculating adjuvant. Similarly U.S. Patent
No. 3,956,519 describes a process in which aggregation of a protein in aqueous solution is induced by dissolved debranched low-DE maltodextrin or debranched amylopectin. In the pharmaceutical sector, xanthan gum is utilized in the manufacturing of freeze dried pharmaceutical tablets as described in the WO Application No. 9501782 in which xanthan gum facilitates suspension of the granular therapeutic agents in the liquid admixture and does not have any adverse affects on the dispersion qualities and texture of the tablet upon usage.
On the contrary US 6,010,719 describes use of xanthan gum as a thickening agent, which increases viscosity of the suspension and is suitable for preventing sedimentation of the solid drug particles. Similarly, xanthan gum has also been used to suspend large biological particles for the purpose of stabilizing cell suspensions during flow cytometry, thereby preventing sedimentation (Cytometry 10: 803-806 (1989)). Another example shows that the presence of xanthan inhibited the aggregation and demixing of whey protein isolates and resulted in a homogenous mixture (Food Hydrocolloids 12: 469-479 (1998)).
All these examples however apply to relatively simple intact suspensions of cells or specific proteins.
Cell lysates, on the other hand, result from the lysis of cells, which releases many components in various forms, forming an extremely complex mixture of constituents such as proteins, glycoproteins, polysaccharides, lipids, nucleic acids etc. All these components may interact with each other, significantly increasing the possibility for complex formation and flocculation, ultimately resulting in a non-stable solution or suspension and sedimentation of part of these components. Accordingly, it can be seen that there remains a need to provide a homogenous stable pharmaceutical composition comprising cell lysates. One example of such a composition contains a keratinocyte cell lysate, which is suitable for wound healing purposes. There further remains a need to provide such pharmaceutical composition of cell lysates in the form of a solution or a suspension, which are homogenized and if required further processed by drying or freeze-drying.
Summary of the Invention
The present invention relates to a pharmaceutical composition comprising a cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The present invention further provides a homogeneous pharmaceutical composition in a dried or freeze-dried form.
The present invention provides a pharmaceutical composition comprising a cell lysate and at least one antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant/antisedimentation agent is xanthan gum. The present invention further provides a pharmaceutical composition, in which the antiflocculant and/or antisedimentation agent is a combination of xanthan gum and maltodextrin.
Further, the pharmaceutical composition may comprise a buffering agent. Examples of buffers which are useful in this regard, include citrate buffers, phosphate buffers, or any other suitable buffer known in the art, preferably clinically acceptable buffering agents. The present invention further provides a process for the production of a pharmaceutical composition of cell lysate in the form of a solution or a suspension that is substantially free of inconsistencies. An example of such a pharmaceutical composition is a homogeneous freeze-dried pharmaceutical composition of a keratinocyte cell lysate. The present invention also provides processes for the production of a homogenized, sterilized composition of a keratinocyte cell lysate in the form of a solution or a suspension.
The pharmaceutical composition of the present invention may be useful for various therapeutic applications and may further comprise a pharmaceutically acceptable carrier or vehicle or recipient. One example is a composition of keratinocyte cell lysate useful in the treatment of wounds such as burn wounds or skin ulcers.
The present invention provides a pharmaceutical composition for promoting the healing of a wound; wherein said composition comprises a non-viable keratinocyte lysates and a pharmaceutically acceptable vehicle. The said pharmaceutically acceptable vehicle is a dry powder, suspension or solution. Further in this regard, the said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix other than a gel.
The present invention also provides a process for treating a surface wound to promote healing in a mammal comprising the step of:
(a) applying to said surface wound the pharmaceutical composition; and
(b) promoting healing of said surface wound. The present invention disclosed herein is a pharmaceutical composition of cell lysate in the form of a solution or a suspension, or a freeze-dried form thereof, further characterized in that it is substantially free of inconsistencies. This solution or suspension of the cell lysate or the freeze-dried form thereof comprises xanthan gum and or maltodextrin that acts as an anti-flocculant agent(s) for preventing the formation of flocculants in the solution or suspension that may sediment.
The present invention discloses a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture. The said agent is xanthan gum or combination of xanthan gum and maltodextrin which prevents the formation of flocculants at may sediment in the solution or suspension. Furthermore, this process may optionally include the freeze-drying or otherwise drying of the solution or suspension to obtain a water- free product.
Detailed Description of the Invention
A pharmaceutical composition of the present invention is a composition of cell lysate in the form of a solution or a suspension. These pharmaceutical compositions containing a cell lysate further comprise a buffer component and at least one anti-flocculant and/or anti-sedimentation agent. These compositions may be further processed by freeze-drying or otherwise drying, resulting in a substantially water-free product with even better long- term stability.
Within the context of this invention, the term "inconsistencies" refers to the situation where the composition of the cell lysate is not homogeneous, in such a way that the composition of one part of the lysate may differ from the composition of another part of the lysate. The term "cell lysate" refers to non-viable cell suspensions or fractions thereof, obtained by lysing the cells. The cell lysate in the solution or suspension of the present invention may be whole cells, parts of cells or any fractions or mixtures thereof obtained after a lysis step. The cell lysate may be obtained by any of the various processes which are well-known to those skilled in the art. For example, whole cells may be obtained as described in US 6,126,935. Parts of cells may be obtained by lysing whole cells, subjecting the resulting lysate to centrifugation wherein certain parts of the resulting cell lysate are in the pellet fraction and certain other parts of the resulting cell lysate are in the supernatant and only one of the two parts are used. An example of such a process is disclosed in US 6,126,935.
The term "cell lysis" refers to any type of cell (i.e. prokaryotic or eukaryotic) and involves the action of rapturing the cell wall and/or the cell membrane of cells (present in the form of solution or suspension) subjected to a treatment which may include chemical, biological, mechanical or thermal treatment, possibly resulting in the release of its biological constituents.
Numerous mechanical methods for lysis have been developed and published. They include pressure, cavitation, sonic or ultrasonic waves, mechanical shaking or grinding (Sadeva, Biopharm 7(2): 26-36, 1994). Cell lysates may be obtained by mechanically homogenizing the cells. The Keratinocyte cell lysates of the present invention may preferably be obtained by a process as described in US 6,126,935.
It should be understood that the term "homogenization or homogenizing" used in the present context denotes the processing of the cell lysate mixture by making the said mixture homogeneous in such a way as to ensure that any given part of the above mentioned mixture has the same composition and physico-chemical properties as any
other part of that same mixture. The term homogenization or homogenizing may also refer to lysis in the sense that certain homogenization procedures also lead to cell lysis. The concentration of cell lysate in a composition of the present invention varies according to the type of cell lysate in the composition, as well as according to its intended use. In this regard, the concentration of cell lysate ranges from 0.02 to 5 % w/v (percentage refers to weight percentage of total protein in the cell lysate, as deteπnined by a suitable protein quantification assay). Preferably, the concentration of the cell lysate ranges from 0.05 to 2 % w/v. More preferably, the concentration of the cell lysate ranges from 0.1 to 1 % w/v. The liquid component of the solutions/suspensions of the present invention may be any liquid suitable for supporting the cell lysate in the solution or suspension. Examples of such liquid components are water, oil, or emulsions (such as water-in-oil or oil-in-water emulsions) and other similar liquids. In cases involving a pharmaceutical composition of keratinocyte cell lysates of the present invention, the use of an isotonic solution of sodium chloride (for osmotic adjustment), phosphate buffer and lysed cells is contemplated. Preferably, this is supplemented with a solution of a lyoprotectant (such as sucrose, maltodextrin, glycine, sorbitol, trehalose, polyvinylpyrrolidone, polyethylene glycol or any other suitable lyoprotectant or combination thereof) and a citrate buffer (such as sodium citrate) for aiding the subsequent freeze-drying of the composition.
A pharmaceutical composition of the present invention in addition may contain other buffers or buffer systems. Examples of such buffers may include phosphate, citrate or any other compositions, which can act as a pH-buffer. In a particular embodiment, the present invention involves a pharmaceutical composition obtained by a process comprising the step of lysing the cells prior to adding at least one anti-flocculant and/or anti-sedimentation agent to the composition of a non-viable cell lysate solution or suspension.
In a particular embodiment, the present invention provides a pharmaceutical composition comprising a cell lysate and antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant/antisedimentation agent is xanthan gum
Xanthan gum may be obtained commercially or by fermentation. The concentration of xanthan gum in the pharmaceutical composition of cell lysate of the present invention will range from 0.001 to 5 % w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5 % w/v. In a particular embodiment the present invention involves a pharmaceutical composition of keratinocyte cell lysate, the use of xanthan gum aids in preventing flocculation and sedimentation in the keratinocyte cell lysate solution or suspension prior to or during use or further processing. Accordingly, the formation of inconsistencies in the solution or suspension is avoided. This facilitates further processing and use of the keratinocyte cell lysate solution or suspension for the formation of a composition useful in wound healing, for example, for the treatment of skin ulcers or burns.
In a particular embodiment, the present invention provides a pharmaceutical composition comprising a cell lysate and antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant/antisedimentation agent is maltodextrin. The concentration of maltodextrin in the solutions/suspensions of the present invention may range from 0.01 to 10 % w/v. Alternatively; a concentration of maltodextrin ranging from 0.5 to 2 % w/v may be used.
In this regard, it is noted that in certain circumstances, it is desirable for the composition of the present invention to have a particular pH and/or be maintained within a specific pH range. For example, for a pharmaceutical composition of keratinocyte cells of the present inventions, it is preferred to maintain the composition at a pH of substantially 6.8. Accordingly, a buffer is employed for this purpose. Examples of buffers which are useful in this regard, include citrate buffers, phosphate buffers, or any other suitable buffer known in the art, preferably also clinically acceptable. The precise concentration of buffer to include in the final solution or suspension will vary according to various factors including the strength of the buffer and the pH, which is required for the composition. Nonetheless, it is contemplated herein that, where keratinocyte lysate suspensions are involved, the final concentration of buffer in the composition of the invention will range from 5 to 200 mM, preferably from 10 to 100 mM, more preferably from 20 to 50 mM. This can be achieved by adding a concentrated buffer stock solution, for instance with a concentration of approximately 1500 mM, to the composition.
In the event the pharmaceutical compositions and particularly if the solutions/suspensions of the present invention are to be dried or freeze-dried, they may further include sucrose. The concentration of sucrose in the composition of the present invention will vary according to the type of composition, as well as according to the use to which the composition will be placed. In this regard, the concentration of sucrose ranges from 1 to 30 % w/w, preferably from 2 to 20 % w/w, more preferably from 5 to 10 % w/w. This can be achieved by adding sucrose powder or a concentrated sucrose stock solution, for instance with a concentration of approximately 50 %, to the composition. It will be clear that instead of sucrose, a suitable concentration of another lyoprotectant may also be used, such as glycine, trehalose, sorbitol, polyvinyl pyrrolidone, polyethylene glycol or any other suitable lyoprotectant or combination thereof known in the art. The pharmaceutical composition of the present invention may further include such other and different ingredients as may be desirable for the particular cell lysate implicated and/or use for which the composition is intended. It is possible that the solutions/suspensions of the present invention may further include additional components, some of which being a consequence of obtaining the biological (cellular) material. Examples of such ingredients include proteins, culture media, washing media and other organic and/or inorganic material that has a tendency to flocculate and/or sediment or provoke the flocculation and/or sedimentation of the other constituents.
The precise concentration of these additional components may vary greatly depending upon the composition, the use to which the composition will be placed and the precise additional component in question. In a particular embodiment, the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture.
In a particular embodiment, the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and
drying the cells, which process is characterized in that, immediately after lysing, xanthan gum is added as a antiflocculant and/or antisedimentation agent to stabilize the cell lysate mixture.
In a particular embodiment, the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, a mixture of xanthan gum and maltodextrin is added as antiflocculant and/or antisedimentation agents to stabilize the cell lysate mixture. In a particular embodiment, the present invention involves a process for the production of various pharmaceutical compositions of biological materials in the form of a solution or a suspension or freeze-dried solution or suspension, including compositions used to produce a composition of cell lysate in the form of a solution or a suspension or freeze- dried solution or suspension. Of particular utility is the use of the process of the present invention to produce a composition of keratinocyte cell lysate in the form of a solution or a suspension or freeze-dried solution or suspension.
The solution or suspension is formed by combining (such as, for example, by mixing) the cell lysate, obtainable by any process known to those skilled in the art, with one or more suitable excipients, possibly in a liquid form. This may be achieved by any process well known to those skilled in the art, which is suitable for use with the particular biological material andor liquid component involved. It is anticipated herein (and as was discussed above), particularly in cases wherein a keratinocyte cell lysate is involved, that the solution or suspension of cell lysate will be formed by obtaining the cell lysate and the excipients (possibly in liquid form), either individually or at the same time, and mixing the cellular matter with the excipients in such a manner that a solution or a suspension of the cell lysate is formed.
The keratinocyte cell lysate may be prepared in the form of an isotonic solution of sodium chloride 0.9 % (w/w), phosphate-buffered saline or any other suitable medium. The cell lysate is then homogenized mechanically and may be stored if required at -70°C. The frozen homogenate is then thawed and supplemented with the addition thereto of the excipients comprised of sucrose to a final concentration of 6.5 % (as a lyoprotectant) and citrate buffer to a final concentration of 30 mM
The concentration of cell lysate and the liquid component to be added to the composition in the process of the present invention will vary according to the type of cell lysate in the composition, as well as according to its intended use.
Adding the xanthan gum to the suspension or solution of cell lysate may be performed in any suitable manner well-known to those skilled in the art. For example, this may be done by adding the xanthan gum in its solid state to the solution or suspension under conditions which facilitate its dissolution and homogeneous distribution throughout the solution or suspension or it may be first dissolved in a liquid, such as water, before being added to the suspension/solution of cell lysate. As was noted above, the addition of this xanthan gum, immediately after the homogenization still permits the xanthan gum to exercise its anti-flocculation/anti-sedimentation properties without subjecting the xanthan gum to the homogenization process which negatively impacts its viscosity properties. In a particular embodiment, the process for the production of a composition of cell lysate that is in the form of a solution or a suspension of the present invention may further comprise homogenization of the formed composition of cell lysate of the present invention prior to the adding of the xanthan gum thereto.
Homogenization may be performed by using any known suitable homogenization techniques which is well known to those skilled in the art, including mechanical and chemical processes, and under such process conditions as is needed to lyse the cells as needed.
Of particular importance in this regard for keratinocyte lysate solutions/suspensions is homogenizing the solution or suspension by high-pressure homogenization. Such homogenization may be conducted using any appropriate apparatus, such as a cell breaker (Constant systems, U.K.). In this particular embodiment, homogenization is conducted at a pressure of 2000 bar between 4 and 20°C. The result is a cell lysate in the form of a suspension. In this regard, it is noted that traditionally, anti-flocculants are added to compositions of cell lysate before homogenization. This is done for ease of processing and to help prevent flocculation during homogenization. However, this also may negatively impact on the viscosity properties of the anti-flocculant, especially in case xanthan gum is used as an antiflocculant, resulting in inconsistencies forming in the composition.
Surprisingly, we have found herein that, the presence of an anti-flocculant agent and/or anti-sedimentation agent in the composition is not needed before homogenization. We have found that, should the anti-flocculant agent and/or anti-sedimentation agent be added to the composition immediately after the (high-pressure) homogenization, flocculation in the composition is still substantially prevented while the viscosity properties of the anti-flocculant are not negatively impacted. The process for the production of a composition of cell lysate that is in the form of a solution or a suspension of the present invention may further be comprised of adding a citrate buffer and/or sucrose (both being obtained as described above) to the compositions of cell lysate of the present invention in concentrations, as were also set forth above.
As disclosed herein, the compositions and the processes of the present invention are of particular application in and of particular interest to the formation of a pharmaceutical composition of keratinocyte cell lysates that are in the form of a solution or a suspension. In this regard, keratinocyte cell lysates may be obtained as described in US 6,126,935. In a particular embodiment, disclosed herein is a pharmaceutical composition of cell lysates in the form of solutions or suspensions and, more particularly keratinocyte cell lysate in the form of a solution or a suspension, or freeze-dried forms thereof at concentrations ranging from 0.2-50 mg/ml, preferably 5-20 mg/ml, more preferably 1-10 mg/ml (the concentrations provided refer to the concentration of protein within the lysate). These solutions/suspensions of cell lysate include xanthan gum that acts as an anti-flocculant agent for preventing the formation of flocculants that may sediment in the solution or suspension. The final concentration of xanthan gum in the pharmaceutical composition (in form of solution or suspension) of the cell lysate of the present invention will range from 0.001 to 5 % w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5 % w/v.
In a particular embodiment, the pharmaceutical composition of cell lysate of the present invention may further include maltodextrin that acts as an anti-flocculant agent for preventing the formation of floccules that may sediment within the solution or suspension. In one embodiment, the final concentration of maltodextrin in a pharmaceutical
composition of cell lysate of the present invention may range from 0.01 to 10 % w/v, more preferably 0.1 to 5 % w/v most preferably 0.5 to 2 % w/v.
In another embodiment, a pharmaceutical composition of cell lysate of the present invention may further include a citrate buffer and/or sucrose. In a particular embodiment, a pharmaceutical composition of cell lysate of the present invention may further include an excipient and, in particular, a gel-foπning excipient.
In a particular embodiment of the present invention, the composition of cell lysate of the present invention is homogenized.
In another particular embodiment of the present invention, the homogenized composition is further processed by drying. Drying may be performed in various ways known in the art, such as evaporation, vacuum-drying, spray drying, fluidized bed drying, infrared drying, microwave drying or otherwise removing the water present in the solution or suspension, as long as the drying process does not negatively impact the properties of the final composition. One of the many preferred methods for removing the water is by freeze-drying.
In a particular embodiment of this aspect of the present invention, the process of the present invention is used to produce a composition of cell lysate in the form of a solution or a suspension and, more particularly, a composition of keratinocyte cell lysate in the form of a solution or a suspension, possibly in a dried form. In one embodiment, the final concentration of xanthan gum added to the pharmaceutical composition of cell lysate of the present invention may range from 0.001 to 5 % w/v. In another embodiment, the concentration of xanthan gum may range from 0.05 to 0.5 % w/v.
In a particular embodiment, the process for the production of a composition of cell lysate that is in the form of a solution or a suspension of the present invention may further include adding maltodextrin to the composition of cell lysate, whereby the maltodextrin acts as an anti-flocculant agent for preventing the formation of flocculants that may sediment within the solution or suspension.
In a particular embodiment, the final concentration of maltodextrin added to a pharmaceutical composition of cell lysate of the present invention may range from 0.01
to 10 % w/v. For most applications, a concentration of maltodextrin ranging from 0.5 to 2 % w/v may be adequate.
In a particular embodiment, the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing by a high-pressure homogenization, a mixture of xanthan gum and/or maltodextrin are added as a antiflocculant and/or antisedimentation agents to stabilize the cell lysate mixture. In a particular embodiment, the present invention involves a process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying of keratinocyte cells, which process is characterized in that, immediately after lysing by a high-pressure homogenization, a mixture of xanthan gum and/or maltodextrin is added as a antiflocculant and/or antisedimentation agents to stabilize the keratinocyte cell lysate mixture.
In still another aspect of the present invention, disclosed herein are pharmaceutical compositions of cell lysate in the form of a solution or a suspension of the present invention obtainable by a process of the present invention.
In a particular embodiment of this aspect of the present invention, disclosed herein are pharmaceutical compositions of keratinocyte cell lysate in the form of a solution or suspension obtained by the process of the present invention. In further particular embodiments, a pharmaceutical composition comprising a keratinocyte cell lysate is in a freeze-dried or otherwise dried form.
In another particular embodiment of the present invention, disclosed herein is a method for treatment of wounds by administering a composition containing an efficient amount of cell lysate or fractions of cell lysates. Furthermore the composition can be administered via different carrier systems and drag dosage forms such as creams, ointments, gels, powders, sprays, solutions, suspensions, emulsions, lyopliilized powders, aerosols.
In another particular embodiment of the present invention, disclosed herein is a composition of a cell lysate in the form of a solution or a suspension obtained by a process including forming a cell lysate in the form of a solution or a suspension, adding at least one anti-flocculant and or at least one anti-sedimentation agent to the composition
of a cell lysate in the form of a solution or suspension and stabilizing the composition of a cell lysate solution or suspension to which the at least one anti-flocculant and/or at least one anti-sedimentation agent has been added.
In a particular embodiment, disclosed herein is a composition of a cell lysate solution or suspension of the present invention obtainable by a process comprising the step of lysing the cells prior to adding at least one anti-flocculant and/or at least one anti-sedimentation agent to the composition of a non-viable cell lysate solution or suspension. One such method of lysing may be by high-pressure homogenization. a a particular embodiment, disclosed herein is a composition of a cell lysate solution or suspension of the present invention obtainable by a process comprising the step of lysing the cells prior to adding xanthan gum at a concentration ranging from 0.001 to 5% w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5% w/v as a anti-flocculant and/or at least one anti-sedimentation agent to the composition of a non-viable cell lysate solution or suspension. One such method of lysing may be by high-pressure homogenization.
In a particular embodiment, disclosed herein is a composition of a cell lysate solution or suspension of the present invention obtainable by a process comprising the step of lysing the cells prior to adding a combination mixtures thereof of xanthan gum at a concentration ranging from 0.001 to 5% w/v, more preferably 0.01 to 1% w/v, most preferably 0.05 to 0.5% w/v and maltodextrin at concentration ranging from 0.01 to 10% w/v, more preferably 0.5 to 2% w/v as anti-flocculant and/or at least one antisedimentation agents to the composition of a non-viable cell lysate solution or suspension. One such method of lysing may be by high-pressure homogenization. In another embodiment, the process for the production of a composition of cell lysate that is in the form of a solution or a suspension (possibly in a dried or freeze-dried form) of the present invention may be further comprised of sterilizing the composition of cell lysate following adding the xanthan gum thereto. Such sterilization may be performed chemically, by heat treatment (including the use of microwave energy) or by irradiation, such as UN, gamma or electron beam irradiation. In case of gamma or electron beam irradiation, the sterilization is performed preferably on the composition after drying (such
as freeze-drying or spray drying), in order to minimize possible effects on the biological activity of the composition.
Having thus described the compositions of cell lysate of the present and the processes for their production, the following examples are now presented for the purposes of illustration only and are not meant to be, nor should they be, read as being restrictive. Modifications of the compositions, processes, uses and methods disclosed above may be made without departing from the basic spirit of the invention. Accordingly, it will be appreciated by those skilled in the art that within the scope of the appended claims, the invention may be practiced other than has been specifically described herein.
EXAMPLES
Example 1: Culturing of human keratinocytes and preparation of a keratinocyte cell lysate Keratinocytes are isolated from neonatal human foreskin. A foreskin specimen is incubated overnight at 4°C in a solution containing 25U/mL Dispase in order to obtain separation of epidermis and dermis. The epidermal part is collected and further processed by incubation for 30 minutes at 37°C in a solution containing 0.05 % trypsin and 0 .02 % EDTA in order to obtain single keratinocyte cells. The trypsin is then neutralized by adding a trypsin inhibitor and the cells are centrifuged, resuspended in a DMSO-containing cryopreservation solution and cryopreserved in liquid nitrogen.
After thawing, isolated keratinocytes are cultured using the 3T3 feeder fibroblast technique (Rheinwald J and Green H. Cell (1975) 6: 331-344: Serial cultivation of strains of human epidermal keratinocytes: the formation of keiatinizing colonies from single cells) or in a commercially available low calcium keratinocyte medium. After culturing, the cells are collected mechanically by scraping in an isotonic solution containing sodium chloride and phosphate buffer, homogenized mechanically and frozen at -70°C. After thawing the thus obtained crude lysate (Bulk Unprocessed Product) is supplemented with a lyoprotectant (sucrose) and citrate buffer and further processed by high pressure homogenization, using a cell breaker (Constant Systems, U.K). The resulting suspension (Bulk Formulated Lysate) is then filled in to vials and lyophilized.
Example 2: Use of xanthan gum and/or maltodextrin to prevent flocculation and sedimentation
Unprocessed bulk lysate (BUP) was prepared as described in example 1. Formulated bulk product constituted 200 g of BUP (containing approx. 2 mg/ml of total protein) to which 13g of sucrose powder was added. This material was divided into three aliquots and processed as follows:
Aliquot IA was processed through a Constant Systems high-pressure homogenizer at 800 bar (one cycle). After processing, 12.5 ml of the homogenized material was supplemented with either :
- 1.25 ml of water (IAl)
- 0.33 ml of a 20% w/v solution of Lutrol F127 (IA2)
- 1.25 ml of a solution of 1% w/v xanthan gum/10% w/v maltodextrin (IA3)
- 1.25 ml of a solution of 1% w/v xanthan gum/10% w/v maltodextrin and 0.32 ml of a solution of 20% w/v Lutrol F127 (IA4)
- Aliquot IB was processed through a Constant Systems high-pressure homogenizer at 2000 bar (one cycle). After processing, 12.5 ml of the homogenized material was supplemented with either :
- 1.25 ml of water (IBl) - 0.33 ml of a 20% w/v solution of Lutrol F127 (EB2)
- 1.25 ml of a solution of 1% w/v xanthan gum/10% w/v maltodextrin (IB3)
- 1.25 ml of a solution of 1% w/v xanthan gum/10% w/v maltodextrin and 0.32 ml of a solution of 20% w/v Lutrol F127 (IB4)
- Aliquot II was further subdivided into 4 aliquots of 25 ml which were first supplemented with either :
- 2.5 ml water (HI)
- 0.65 ml of a 20% w/v solution of Lutrol F127 (112)
- 2.5 ml of a solution of 1 % w/v xanthan gum/10% w/v maltodextrin (113) - 2.5 ml of a solution of 1% w/v xanthan gum/10% w/v maltodextrin and
0.65 ml of a solution of 20% w/v Lutrol F127 (114).
These formulated samples were then passed through the high-pressure homogenizer at either 800 bar (TIIA, H2A, H3A, H4A) or 2000 bar (TUB, II2B, II3B, H4B). The aliquots of processed formulated bulk product were filled into clear plastic 15-ml tubes, which were placed at 2-8°C without disturbing. For this and all following examples, visual
evaluation of flocculation or sedimentation was done at regular intervals, using a scoring system on a 0-5 scale (0/0= no flocculation/sedimentation, 5/5 is maximal flocculation/sedimentation, 5/0 is maximal flocculation, no sedimentation, etc.) The results were evaluated after 2 hrs at 4°C and are summarized in Table 1: 5 Table 1:
L = Lutrol F127; M = maltodextrin; X = xanthan gum; ', hardly any visible flakes, homogeneous and no sediment; 2 possibly poor mixing of Lutrol-MX after homogenization
10 This example shows that the combination of 1% maltodextrin and 0.1% xanthan gum suppresses the flocculation and sedimentation of lysate material. However, surprisingly this beneficial effect is observed only when the additives are added after, and not before, the high-pressure homogenization. Moreover, the addition of maltodextrin and xanthan gum does not negatively interfere with the biological
15 activity of the lysate.
Example 3: Use of xanthan gum/maltodextrin to prevent flocculation and sedimentation of concentrated lysate suspension Preparation of unprocessed bulk lysate (BUP) was done as described in example: 1. - Preparation of formulated bulk product was as follows :
1) To 105 ml BUP, 87.5 ml citrate buffer (120 mM, pH 6.8) was added solution 1
2) To 128 ml of solution 1 , 15 g of sucrose powder was added (solution 2)
Formulation A (no antiflocculant): 64 ml of solution 2 was processed through a Constant Systems homogenizer at 800 bar and then supplemented with 52 ml of water
Formulation B (with antiflocculant): 64 ml of solution 2 was processed through a Constant Systems homogenizer at 800 bar and then supplemented with
29 ml of water and 23 ml of a solution containing 5% maltodextrin and 0.5% xanthan gum 3) Formulation C (with antiflocculant, no sucrose): 64 ml of solution 1 was processed through a Constant Systems homogenizer at 800 bar and then supplemented with 29 ml of water and 23 ml of a solution containing 5% maltodextrin and 0.5% xanthan gum
After processing the samples were stored at 4°C for 24 hrs and flocculation/sedimentation was scored using a 0-5 scale (0= no flocculation/sedimentation, 5 = maximal flocculation/sedimentation). Samples were also lyophilized, treated by electron beam sterilization and evaluated for biological activity. Results are shown in Table 2:
Table 2:
S: sucrose, 6.5%; C: citrate 30 mM, pH 6.8; M: maltodextrin 1%; X: xanthan gum 0.1%; H, after homogenization; L, after lyophilization; L+E, after lyophilization and 31 kGy electron beam irradiation.
These data indicate that the addition of 1% maltodextrin/0.1% xanthan gum in the presence of citrate buffer inhibits flocculation and sedimentation of a low concentration lysate for up to 24 hrs. However, when using a higher concentrated lysate and omitting the citrate buffer, significant flocculation and sedimentation is already evident at 1.5 hrs after homogenization. The data further confirm that maltodextrin and xanthan gum do not negatively influence the bioactivity of the lysate and are compatible with electron beam irradiation (although the intrinsic bioactivity of the lysate is decreased by irradiation).
Example 4: Use of xanthan gum or xanthan e im/maltodextrin to prevent flocculation and sedimentation of lysate suspensions containing different protein concentrations - Preparation of unprocessed bulk lysate (BUP) as described in example 1 Preparation of formulated bulk product:
1. Formulation 3XA and 3XB: - BUP (approx. 0.98 mg/ml): 94g
- 300 mM citrate buffer pH 6.8: 20g
- Sucrose powder: 13g
- Water: 33g
Processing through high pressure homogenizer at 2000 bar - After processing the lysate was divided in two aliquots of 80 g to which either
20 g of a solution containing 5% maltodextrin/0.5% xanthan gum (Formulation 3XA) or 20 g of a solution containing 0.5% xanthan gum (formulation 3XB) was added.
2. Formulation lXA and lXB: - BUP (approx. 0.98 mg/ml): 30.3g
- 300 mM citrate buffer pH 6.8: 20g
- Sucrose powder: 13.2 g
- Water: 96.5g Processing through high pressure homogenizer at 2000 bar - After processing the lysate was divided in two aliquots of 80 g to which either
1XA) or 20 g of a solution containing 0.5% xanthan gum (formulation 1XB) was added. 3. Formulation 0.3XA and 0.3XB: Formulation 0.3XA is prepared by adding the following components to 25g of formulation 1XA :
- sucrose : 3.25g
- 300 mM citrate buffer pH 6.8 : 5g
- PBS buffer : 31.75 g
- 5%maltodextrin/0.5% xanthan gum : lOg
Formulation 0.3XB is prepared by adding the following components to 25g of formulation lXB :
- sucrose : 3.25g
- 300 mM citrate buffer pH 6.8 : 5g
- PBS buffer : 31.75 g
- 5%maltodextrin/0.5% xanthan gum : lOg
The material was stored at 4°C and evaluated for flocculation/sedimentation at different time points. The material was furthermore evaluated for biological activity. The results are summarized in Table 3: Table 3:
(*): Due to unusually low bioactivity in this lysate preparation, bioassay results may be unreliable; M: Maltodextrin 1%; X: xanthan gam 0.1%; C: citrate buffer 30 mM, pH 6.8; S: sucrose: 6.5%
This example shows that, at different final protein concentrations, xanthan gum alone has a comparable efficiency for preventing sedimentation and flocculation as the combination of maltodextrin and xanthan gum.
Example 5: Use of xanthan gum or xanthan gum maltodextrin to prevent flocculation and sedimentation of lysate suspensions and effect of timing of adding the antiflocculants - Preparation of unprocessed bulk lysate (BUP) as described in example 1 Preparation of formulated bulk product:
1. Formulation A and B (no sucrose):
- BUP (approx. 2.74 mg/ml): 27.9 g
- 300 mM citrate buffer pH 6.8: 20g - Water: 112.1g Homogenization through high pressure homogenizer at 2000 bar.
Homogenized material was divided over 2 aliquots of 80 g each to which either 20 g of a solution containing 5% maltodextrin/0.5% xanthan gum (formulation A) or 20 g of a solution containing 0.5 xanthan gum (formulation B) was added.
2. Formulations C-J (with sucrose): - BUP (approx. 2.74 mg/ml): 111.5 g
- 300 mM citrate buffer pH 6.8: 80 g
- Sucrose powder: 52.1 g - Water: 398. lg
This mixture was divided over 8 aliquots of 80 g each. - Two aliquots were supplemented with either 20 g of a solution containing 5% maltodextrin/0.5% xanthan gum (formulation I) or 20 g of a solution containing 0.5 xanthan gum (formulation J) and subsequently processed through a high pressure homogenizer at 2000 bar.
- Six aliquots were first processed through a high pressure homogenizer at 2000 bar and subsequently supplemented with antiflocculant additives either immediately after homogenization (formulations G, H) or at 5 minutes (formulations E, F) or 30 minutes (formulations C, D) after homogenization. The additives used were either 20 g of a solution containing 5% maltodextrin/0.5% xanthan gum (formulations C, E, G) or 20 g of a solution containing 0.5% xanthan gum (formulations D, F, H).
The processed samples were stored at 4°C and evaluated for flocculation/sedimentation using a 0-5 score. Samples were also tested for biological activity. The results are summarized in Table 4: Table 4:
(*): Due to unusually low bioactivity in this lysate preparation, bioassay results may be unreliable; M: Maltodextrin 1%; X: xanthan gum 0.1%; C: citrate buffer 30 mM, pH 6.8; S: sucrose: 6.5%
This example shows that xanthan gum has a similar efficacy for inhibiting flocculation and sedimentation of the lysate suspension as the combination nraltodextrin/xanthan gum. It also confirms the surprising finding that the addition of the antiflocculant needs to occur after the high pressure homogenization step in order to be effective. Addition of the antiflocculant is preferably done as soon as possible after the homogenization in order to minimize subsequent flocculation.
Example 6: Use of xanthan gum, maltodextrin or xanthan gumΛnaltodextrin to prevent flocculation and sedimentation of lysate suspensions and effect of addition before or after homogenization
- Preparation of unprocessed bulk lysate (BUP) as described in example 1 Preparation of formulated bulk product was done by addition of sucrose to a final concentration of 6.5% (formulations 1,2,3) or maltodextrin to a concentration of 5%
(formulation 4,5). The suspension was subsequently homogenized at a pressure of 800 bar and supplemented with either (percentages refer to final concentrations:):
Formulation 1: Maltodextrin 1%, xanthan gum 0.1%
Formulation 2: Maltodextrin 1%
Formulation 3: Xanthan gum 0.1%
Formulation 4: No additive
Formulation 5: Xanthan gum 0.1% After processing the material was stored at 4°C and evaluated for flocculation/sedimentation at different time points. The results are summarized in Table 5: Table 5:
M: Maltodextrin 1% or 5%; X: xanthan gum 0.1%; S: sucrose: 6.5%
This example shows that the combination of maltodextrin and xanthan gum is more effective at inhibiting flocculation than xanthan gum alone. Use of maltodextrin alone causes a limited inhibition of flocculation but does not inhibit sedimentation over a longer time period.
Example 7: Use of xanthan gum/maltodextrin to prevent flocculation and sedimentation of lysate suspensions of different concentrations in the presence or absence of sucrose
Preparation of unprocessed bulk lysate (BUP was done as described in example 1
Preparation of formulated bulk product: 1. Formulation A and B (sucrose):
- BUP (approx. 3.1 mg/ml): 30 ml - 150 mM citrate buffer pH 6.8: 20 ml
- Sucrose powder: 6.5 g
Homogenization through high pressure homogenizer at 800 bar. Homogenized material was divided over 2 aliquots of 25 ml each to which either 25 ml water (formulation A) or 15 ml water and 10 ml of a solution containing 5% maltodextrin/0.5% xanthan gum (formulation B) was added.
2. Formulation C (no sucrose) :
- BUP (approx. 3.1 mg/ml): 15 ml
- 150 mM citrate buffer pH 6.8: 10 ml Homogenization through high pressure homogenizer at 800 bar.
To the homogenized material 15 ml water and 10 ml of a solution containing 5% maltodextrin/0.5% xanthan gum (formulation B) was added.
3. Formulation D (higher protein concentration, no citrate buffer) :
- BUP (approx. 3.1 mg/ml): 45 ml
- Sucrose powder: 3.7 g Homogenization through high pressure homogenizer at 800 bar.
To the homogenized material 12 ml of a solution containing 5% maltodextrin/0.5% xanthan gum (formulation B) was added. The samples were stored at 4°C and evaluated for flocculation and sedimentation at different time points and tested for biological activity. The results are summarized in Table 6:
Table 6:
M: Maltodextrin 1%; X: xanthan gum 0.1%; C: citrate buffer 30 mM, pH 6.8; S: sucrose: 6.5% This example shows that the combination maltodextrin 1%/xanthan gum 0.1% significantly inhibits both flocculation and sedimentation of the lysate up to at least 23 hours after homogenization. The presence of sucrose slightly improves
the effect of maltodextrin/xanthan gum. After longer incubation (96 hrs), sedimentation and flocculation occurs even in presence of maltodextrin/xanthan gum, especially at higher protein concentrations. The presence of maltodextrin and xanthan gum does not affect the biological activity of the lysate.
Claims
1. A pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s).
2. The pharmaceutical composition of claim 1 , wherein antiflocculant and/or antisedimentation agent is xanthan gum.
3. The pharmaceutical composition of claims 1 and 2, wherein antiflocculant and /or antisedimentation agent is combination of xanthan gum and maltodextrin.
4. The pharmaceutical composition of claims 1 to 3 further comprising a buffering agent.
5. The pharmaceutical composition of claims 1 to 4 in a dried form.
6. The pharmaceutical composition of claims 1 to 4 in a freeze-dried form.
7. The pharmaceutical composition of claims 1 to 6, wherein the cell lysate is a keratinocyte cell lysate.
8. The pharmaceutical composition of claims 1 to 7, wherein said composition further comprises a pharmaceutically acceptable carrier/excipient/vehicle.
9. The pharmaceutical composition of claims 1 to 8 for the purpose of promoting wound healing, wherein said composition comprises a non-viable cell lysate and a pharmaceutically acceptable vehicle.
10. The pharmaceutical composition of claims 8 and 9, wherein said pharmaceutically acceptable vehicle is a dry powder, a suspension or a solution.
11. The pharmaceutical composition of claims 8 and 9, wherein said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix.
12. A process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture.
13. A process of claim 12 wherein drying the cells is by freeze-drying.
14. A process of claims 12 and 13, wherein cell the lysate is a keratinocyte cell lysate.
15. A process of claims 12 to 14, wherein the antfflocculanl/antisedimentation agent is xanthan gum.
16. A process of claim 12 to 15 wherein the antiflocculant and/or antisendimentation agent is a combination of xanthan gum and maltodextrin. Use of the composition of claim 1 to 11 for the treatment of burn wounds or skin ulcers.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002504801A CA2504801A1 (en) | 2002-12-03 | 2003-11-25 | Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| BR0315414-9A BR0315414A (en) | 2002-12-03 | 2003-11-25 | Pharmaceutical cell lysate compositions and processes for producing and using these |
| JP2004556333A JP2006509779A (en) | 2002-12-03 | 2003-11-25 | Pharmaceutical composition of cell lysate and process and use thereof |
| AU2003298319A AU2003298319A1 (en) | 2002-12-03 | 2003-11-25 | Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| EP03796052A EP1603594A1 (en) | 2002-12-03 | 2003-11-25 | Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| US10/537,301 US7264826B2 (en) | 2002-12-03 | 2003-11-25 | Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02447238.3 | 2002-12-03 | ||
| EP02447238 | 2002-12-03 | ||
| US43391202P | 2002-12-17 | 2002-12-17 | |
| US60/433,912 | 2002-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004050121A1 true WO2004050121A1 (en) | 2004-06-17 |
Family
ID=35931666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2003/050891 WO2004050121A1 (en) | 2002-12-03 | 2003-11-25 | Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7264826B2 (en) |
| EP (2) | EP1603594A1 (en) |
| JP (1) | JP2006509779A (en) |
| CN (1) | CN100369630C (en) |
| AU (1) | AU2003298319A1 (en) |
| BR (1) | BR0315414A (en) |
| CA (1) | CA2504801A1 (en) |
| WO (1) | WO2004050121A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065334A1 (en) | 2006-11-30 | 2008-06-05 | Systagenix Wound Management Ip Co. B.V. | Wound dressing compositions containing non-viable cell lysate |
| WO2019126494A1 (en) * | 2017-12-20 | 2019-06-27 | Cook Regentec Llc | Pathogen reduced platelet compositions and related methods |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236538B2 (en) * | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
| EP2254608B1 (en) * | 2008-02-07 | 2016-05-04 | Shahar Cohen | Compartmental extract compositions for tissue engineering |
| FR2930443B1 (en) | 2008-04-29 | 2010-06-25 | Oreal | EXTEMPORANE CARE PRODUCT BASED ON MICROORGANISM LYOPHILISATE AND SURFACTANT (S) HLB UP TO 12 |
| KR20220110798A (en) * | 2019-12-02 | 2022-08-09 | 아반트 미츠 컴퍼니 리미티드 | Methods for producing meat by in vitro cell culture |
| US11306342B2 (en) | 2019-12-02 | 2022-04-19 | Avant Meats Company Limited | Cell hydrolysate composition from cultivated cells and applications thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387415A (en) * | 1992-01-17 | 1995-02-07 | Alfatec Pharma Gmbh | Aloe vera juice containing pellets process for production thereof and the use thereof as pharmaceutical, cosmetic and peroral agents |
| JPH07267876A (en) * | 1994-03-30 | 1995-10-17 | Sunstar Inc | Composition for stabilizing cell growth factor |
| WO1997041899A1 (en) * | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
| US5866167A (en) * | 1991-11-20 | 1999-02-02 | N.V Innogentics S.A. | Non-viable total keratinocyte lysate for promoting wound healing |
| US6046178A (en) * | 1997-04-18 | 2000-04-04 | Deroyal Industries, Inc. | Method and compound for treating wounds with starch hydrolysate medication |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3956519A (en) | 1973-12-13 | 1976-05-11 | Thomas J. Lipton, Inc. | Process for aggregating protein |
| FR2516397B1 (en) * | 1981-11-16 | 1988-01-15 | Rhone Poulenc Spec Chim | FLOCCULATION ADDITIVE AND PROCESS FOR THE PURIFICATION OF WATER |
| US5804213A (en) * | 1991-10-09 | 1998-09-08 | Lectec Corporation | Biologically active aqueous gel wound dressing |
| US6585969B1 (en) * | 1991-11-20 | 2003-07-01 | N. V. Innogenetics S.A. | Non-viable keratinocyte cell composition or lysate for promoting wound healing |
| US5631023A (en) | 1993-07-09 | 1997-05-20 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US6010719A (en) | 1997-09-16 | 2000-01-04 | Universiteit Gent | Freeze-dried disintegrating tablets |
| US20050079147A1 (en) * | 2003-10-14 | 2005-04-14 | Bernard Delaey | Wound healing compositions and uses |
-
2003
- 2003-11-25 BR BR0315414-9A patent/BR0315414A/en not_active IP Right Cessation
- 2003-11-25 CN CNB2003801049744A patent/CN100369630C/en not_active Expired - Fee Related
- 2003-11-25 JP JP2004556333A patent/JP2006509779A/en active Pending
- 2003-11-25 US US10/537,301 patent/US7264826B2/en not_active Expired - Fee Related
- 2003-11-25 WO PCT/EP2003/050891 patent/WO2004050121A1/en active Application Filing
- 2003-11-25 EP EP03796052A patent/EP1603594A1/en not_active Withdrawn
- 2003-11-25 AU AU2003298319A patent/AU2003298319A1/en not_active Abandoned
- 2003-11-25 EP EP08166048A patent/EP2047865A1/en not_active Withdrawn
- 2003-11-25 CA CA002504801A patent/CA2504801A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866167A (en) * | 1991-11-20 | 1999-02-02 | N.V Innogentics S.A. | Non-viable total keratinocyte lysate for promoting wound healing |
| US5387415A (en) * | 1992-01-17 | 1995-02-07 | Alfatec Pharma Gmbh | Aloe vera juice containing pellets process for production thereof and the use thereof as pharmaceutical, cosmetic and peroral agents |
| JPH07267876A (en) * | 1994-03-30 | 1995-10-17 | Sunstar Inc | Composition for stabilizing cell growth factor |
| WO1997041899A1 (en) * | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
| US6046178A (en) * | 1997-04-18 | 2000-04-04 | Deroyal Industries, Inc. | Method and compound for treating wounds with starch hydrolysate medication |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE WPI Section Ch Week 199550, Derwent World Patents Index; Class B04, AN 1995-390237, XP002274804 * |
| See also references of EP1603594A1 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065334A1 (en) | 2006-11-30 | 2008-06-05 | Systagenix Wound Management Ip Co. B.V. | Wound dressing compositions containing non-viable cell lysate |
| US8834905B2 (en) | 2006-11-30 | 2014-09-16 | Systagenix Wound Management (Us), Inc. | Wound dressing compositions |
| WO2019126494A1 (en) * | 2017-12-20 | 2019-06-27 | Cook Regentec Llc | Pathogen reduced platelet compositions and related methods |
| CN111770777A (en) * | 2017-12-20 | 2020-10-13 | 塞克斯顿生物技术公司 | Pathogen-reducing platelet compositions and related methods |
| GB2583674A (en) * | 2017-12-20 | 2020-11-04 | Sexton Biotechnologies Inc | Pathogen reduced platelet compositions and related methods |
| DE112018006568B4 (en) | 2017-12-20 | 2022-03-03 | Sexton Biotechnologies, Inc. (Gesellschaft nach den Gesetzen des Staates Delaware) | Process for preparing pathogen-reduced platelet compositions |
| GB2583674B (en) * | 2017-12-20 | 2022-10-12 | Sexton Biotechnologies Inc | Pathogen reduced platelet compositions and related methods |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003298319A1 (en) | 2004-06-23 |
| JP2006509779A (en) | 2006-03-23 |
| CN1720064A (en) | 2006-01-11 |
| US20060039989A1 (en) | 2006-02-23 |
| EP2047865A1 (en) | 2009-04-15 |
| CN100369630C (en) | 2008-02-20 |
| US7264826B2 (en) | 2007-09-04 |
| CA2504801A1 (en) | 2004-06-17 |
| BR0315414A (en) | 2005-08-16 |
| EP1603594A1 (en) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021056815A1 (en) | Chemotherapeutic immune drug composition and preparation method thereof | |
| JP6007209B2 (en) | Microparticle-soluble glucan preparation | |
| SOUPART et al. | Sialic acid as a component of the zona pellucida of the mammalian ovum | |
| JP2016526053A (en) | Phytoglycogen nanoparticles and method for producing the same | |
| KR102527607B1 (en) | Plant Derived Extracellular Vesicles, Composition Comprising Thereof, and Method of Producing Thereof | |
| US7264826B2 (en) | Pharmaceutical compositions of cell lysate and processes for the production and use thereof | |
| Ahmadi et al. | Fabrication, characterization and application of novel nanoemulsion polyvinyl alcohol/chitosan hybrid incorporated with citral for healing of infected full-thickness wound | |
| DE112018006568T5 (en) | Pathogen Reduced Platelet Compositions and Related Methods | |
| KR20230121973A (en) | Preparation Process for Polynucleotide Fragments from Plant and Non-Aqueous Composition containing the same | |
| JP6209580B2 (en) | Ultraviolet ray obstruction reducing agent, method for producing ultraviolet ray obstruction reducing agent, medium additive, microorganism diluent additive, medium, microorganism diluent, external preparation and cosmetics | |
| Shishova et al. | The use of nanosized liposomes from vegetable phospholipids in combination with albumine and some polysaccharides as cryoprotective agents in the course of cryopreservation | |
| KR101335788B1 (en) | Method for preparing fermented extract of Gastrodiae elata by using of drip | |
| Lupu et al. | In vivo study of conjugated diminazene aceturate for ichthyophthiriosis of farmed carp | |
| DE3417022C2 (en) | ||
| KR101853547B1 (en) | Complex, process for the preparation thereof, and food or pharmaceutical composition comprising the same | |
| CN116889227A (en) | Exosome freeze-drying protective agent, exosome freeze-drying method and exosome freeze-dried powder | |
| Bendala et al. | Preparation of Wheat Germ Oil Loaded Solid Lipid Nanoparticles for Topical use | |
| Ahmed et al. | In Vitro Evaluation of Nanochitosan Derivatives and Streptomycin on RD Cell Line and Leishmania Tropica | |
| WO2024025479A1 (en) | A process of extraction of porcine placenta protein and development of encapsulating and transporting system of porcine placenta protein extract to control an enteric release | |
| RU2155812C1 (en) | Biotechnological method of wound-healing preparation preparing | |
| CN114306221A (en) | Compound amino acid oral liquid of sheep placenta for veterinary use and preparation method thereof | |
| CN101068556A (en) | Pilose antler nano-products containing enriched insulin-like growth factor and producing method thereof | |
| CN117384312A (en) | Natural molecule-based active agent, preparation method and application thereof | |
| KR20240002224A (en) | Microsphere drug transporters comprising cell secretions derived from canine stem cells and uses thereof | |
| RU2541121C1 (en) | Agent for intracellular delivery of biologically high-molecular compound of nanoparticles and method for preparing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2504801 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003298319 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004556333 Country of ref document: JP |
|
| ENP | Entry into the national phase |
Ref document number: 2006039989 Country of ref document: US Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10537301 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 20038A49744 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003796052 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003796052 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 10537301 Country of ref document: US |